Figure 5.

Pharmacological LPA₁ receptor antagonism attenuates bleomycin-induced fibrosis. (A) H&E (left panels) and Masson’s trichrome staining (right panels) of the skin of PBS- or BLM-challenged C57Bl/6 mice treated with vehicle or AM095 in a ‘preventive’ regimen. Magnification x100; bar, 100μm. (B) Dermal thickness of PBS- or BLM-challenged C57Bl/6 mice treated with vehicle, ‘preventive’ AM095, or ‘therapeutic’ AM095 begun 7 (AM095 #1) or 14 days (AM095 #2) after PBS or BLM. N = 3 mice/group, data expressed as mean dermal thickness ± SEM (*p<0.0008, preventive AM095- vs. vehicle-BLM-mice; **p<0.002 and ***p<0.01, AM095 #1- and AM095 #2- vs. vehicle-BLM-mice, respectively). (C) Skin hydroxyproline content of the same groups of mice in (A). N = 5 mice/group, data expressed as mean hydroxyproline/skin sample ± SEM (*p<0.0005, **p<0.02 and ***p<0.02, vehicle-treated vs. preventive AM095-, therapeutic AM095 #1- and therapeutic AM095 #2-treated BLM-challenged mice, respectively). In (B) and (C), PBS, vehicle-BLM, and preventive AM095-BLM data are combined from 2 experiments; therapeutic AM095-BLM data are from one experiment.